Posaconazole
Posaconazole is a pharmaceutical drug with 49 clinical trials. Currently 5 active trials ongoing. Historical success rate of 91.9%.
Success Metrics
Based on 34 completed trials
Phase Distribution
Phase Distribution
13
Early Stage
9
Mid Stage
19
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.0%
34 of 40 finished
15.0%
6 ended early
5
trials recruiting
49
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
A Study of BGB-11417 in Participants With Myeloid Malignancies
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
Clinical Trials (49)
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
A Study of BGB-11417 in Participants With Myeloid Malignancies
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
PTX3-targeted Antifungal Prophylaxis
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
Registry of Patients Treated With Systemic Mold-Active Triazoles
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity
Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)
Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children
Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir
Modified Release Posaconazole in Patients With Cystic Fibrosis
King's Invasive Aspergillosis Study II
HDM201 Added to CT in R/R or Newly Diagnosed AML
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 49